AstraZeneca sells ciclesonide rights
AstraZeneca
11,352.00p
16:40 24/04/24
AstraZeneca will sell the rights to asthma medicine Alvesco and rhinitis medicines Omnaris and Zetonna to Covis Pharma for up to $371m.
FTSE 100
8,040.38
16:34 24/04/24
FTSE 350
4,419.71
17:09 24/04/24
FTSE All-Share
4,374.06
16:44 24/04/24
Pharmaceuticals & Biotechnology
21,897.50
17:09 24/04/24
The agreement will cover ex-US markets and US royalties for the medicines, with Covis Pharma currently commercialising Alvesco, Omnaris and Zetonna in the US.
Covis has agreed to pay AstraZeneca an up-front $350m and up to $21m in milestones over four years from 2019.
In combination the drugs delivered total sales of $106m in 2017.
AstraZeneca made no change to its financial guidance for 2018 as a result of the agreement, which represents continuation of ongoing strategy to divest non-core medicines and reinvest the proceeds in the development of new medicines within its core focus areas.